The $100 Billion Weight Loss Revolution That's Reshaping Your Portfolio

Related Articles

Is Viking Therapeutics Poised to Disrupt the Weight-Loss Market

2 months ago

SanDisk Just Joined the S&P 500—Here's What That Actually Means for Your Portfolio

6 months ago

From Value Meals to Weight-Loss Drugs: Navigating the Evolving Consumer Landscape

3 months ago

Is the AI Revolution Reshaping Mid-Cap Tech

3 months ago

Category

You may also like

Stock News•3 days ago

Inside the GLP-1 Boom: ETF Picks for the Obesity Drug Market

GLP-1 drugs are reshaping healthcare and consumer markets. These ETFs offer targeted exposure to the booming obesity-drug trend.

GLP

Share

Stock News•6 days ago

80% of Wegovy Pill Users Never Took a Weight Loss Drug Before. Does This Number Change the Entire Novo Nordisk Bear Case?

Novo Nordisk reported strong initial sales for its pill-based Wegovy, with 80% of users new to weight loss drugs. Sales are not cannibalizing existing injectable Wegovy products.

NVO

Share

Stock News•3 weeks ago

Patients on Lilly's next-gen obesity drug lost 28% of body weight, company says

Eli Lilly’s experimental obesity drug, retatrutide, helped patients lose over 28% of their body weight during an 18-month trial. These results support the company’s plans to seek regulatory approval a...

LLY

Share

Stock News•4 weeks ago

Peer-Reviewed Research Is Redefining Weight Loss Program Standards

The global weight loss industry reached a $16.3B valuation in 2025, yet clinical validation remains inconsistent. Industry standards are shifting toward randomized controlled trials and body compositi...

MED

Share